Vulvar squamous cell carcinoma
MONDO:0024609An invasive squamous cell carcinoma arising from the vulva. Risk factors include the human papilloma virus and cigarette smoking. Precursor lesions include the vulvar intraepithelial neoplasia, lichen sclerosus with associated squamous cell hyperplasia, and chronic granulomatous vulvar disease such as granuloma inguinale. Symptoms include vulvar pruritus or irritation, discharge, bleeding, and pain. The following morphologic variants have been identified: keratinizing, non-keratinizing, basaloid, warty, verrucous, keratoacanthoma-like, and squamous cell carcinoma with tumor giant cells. Risk factors for recurrence include advanced stage, tumor diameter greater than 2.5 cm, multifocality, capillary-like space involvement, associated vulvar intraepithelial neoplasia grades 2 or 3, and margins of resection involved by tumor. (WHO, 2003)
Also known as: epidermoid carcinoma of the vulva, epidermoid carcinoma of vulva, epidermoid cell carcinoma of the vulva, epidermoid cell carcinoma of vulva, mammalian vulva squamous cell carcinoma, squamous cell carcinoma of the vulva, squamous cell carcinoma of vulva, vulva epidermoid carcinoma
2859 clinical trials for this condition and its sub-types, 22 tagged with Vulvar squamous cell carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Vulvar squamous cell carcinoma
-
1 sub-type
-
Vulva verrucous carcinoma 0 trials
-
Can a smart drug shrink rare gynecologic tumors?
Disease control Not yet recruitingThis phase II trial tests whether sacituzumab tirumotecan (Sac-TMT) can shrink tumors in people with advanced or metastatic squamous cell carcinoma of the vagina or vulva. These cancers are rare, and there is no standard second-line treatment. Sac-TMT is an antibody-drug conjugat…
Phase 2 • Sponsor: Latin American Cooperative Oncology Group • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Two-Drug combo aims to shrink vulvar tumors before surgery
Disease control Not yet recruitingThis trial tests whether combining an immune-boosting cream (imiquimod) with a low dose of an immunotherapy drug (nivolumab) can shrink vulvar squamous cell carcinoma tumors before surgery. About 50 women with resectable, early-to-moderate stage vulvar cancer will receive the dru…
Phase 1/2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Targeted drug shows promise for rare vulvar cancer
Disease control Not yet recruitingThis phase 2 trial tests a drug called tisotumab vedotin in people with advanced squamous cell carcinoma of the vulva that has returned or spread. The drug is an antibody-drug conjugate designed to seek out and destroy cancer cells. The study aims to see how many participants' tu…
Phase 2 • Sponsor: GOG Foundation • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Glow-in-the-Dark dye could simplify vulvar cancer surgery
Diagnosis Not yet recruitingThis pilot study will test whether a fluorescent dye called indocyanine green (ICG), used with a special handheld camera, can find sentinel lymph nodes as well as the standard blue dye in early-stage vulvar cancer. Ten patients will receive both dyes during surgery, and doctors w…
Sponsor: Tufts Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 07:52 UTC